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tions. However, the potential toxicities
that may be associated with immuno-
therapy targeted at angiogenic agents
should not dampen our enthusiasm for
moving these strategies through preclini-
cal studies, but rather should ignite the
desire to move forward quickly with a
watchful eye toward rationally designed
clinical trials.
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Nuclear factor of κB (NF-κB) defines a
family of related homo- and heterodimer-
ic transcription factors (Ghosh and Karin,
2002). It includes proteins that are syn-
thesized in their mature form and pro-
teins that are synthesized as large
precursors that undergo proteolytic pro-
cessing. The first group encompasses
RelA, RelB, and c-Rel, which have an N-
terminal Rel homology domain (RHD),
required for DNA binding and dimeriza-
tion, and a C-terminal region with trans-
activating properties (Figure 1). These
proteins are held in the cytoplasm by
“Inhibitors of κB” (IκB) proteins, charac-
terized by 6–7 ankyrin repeats that are
required for binding to the RHD of Rel
proteins and masking their nuclear local-
ization sequences. Upon cell stimulation,
the IκBs are phosphorylated and under-
go ubiquitin-dependent degradation. The
liberated NF-κB dimers enter the
nucleus and act as sequence-specific
transcription factors. The second group
consists of NF-κB1/p105 and NF-
κB2/p100 and their products p50 and
p52, respectively.The precursors contain
an N-terminal RHD as well as a C-termi-
nal region that contains ankyrin repeats
similar to those in IκBs (Figure 1). In their
C terminus, the precursors contain a
death domain (DD). By virtue of their
ankyrin repeats and their ability to dimer-
ize with other Rel proteins, p105 and
p100 act like IκBs (Mercurio et al., 1993).
While p105 processing is largely consti-
tutive, processing of p100 is triggered by
its phosphorylation and ubiquitination in
a manner akin to IκB degradation (Xiao
et al., 2001). Limited proteolysis results
in generation of the mature NF-κB2/p52
transcription factor consisting of the N-
terminal RHD.
The pathways that lead to activation
of NF-κB and processing of p100 depend
on components of the IκB kinase (IKK)
complex, which contains two catalytic
subunits, IKKα and IKKβ, and a regulato-
ry subunit IKKγ/NEMO (Rothwarf et al.,
1998). After activation by stimuli like the
proinflammatory cytokine TNFα or bacte-
rial products such as LPS, IKKβ phos-
phorylates the IκBs, leading to their
degradation and nuclear entry of NF-κB
dimers. This pathway, named the canoni-
cal NF-κB activation pathway, applies pri-
marily to NF-κB dimers composed of
RelA, c-Rel, and p50. An alternative NF-
κB signaling pathway involving IKKα
leading to p100 processing has recently
been described (Senftleben et al., 2001).
This pathway is triggered upon occupan-
cy of BAFF (B cell activating factor)
receptor (BAFF-R) and CD40 on B cells
and lymphotoxin β receptor (LTβR) on
stromal cells. Activation of this pathway
results in disappearance of p100 and
nuclear translocation of p52:RelB dimers
(Dejardin et al., 2002; Senftleben et al.,
2001; Xiao et al., 2001). Processing of
p100 depends on the catalytic activities
of IKKα and another kinase, NIK, which
probably acts upstream of IKKα
(Senftleben et al., 2001). The function of
this pathway is still not well defined, but it
is likely to be required for B cell matura-
tion and formation of secondary lymphoid
organs (Senftleben et al., 2001). The DD
of p100 is also involved in processing, as
its removal leads to constitutive process-
ing as well as inhibition of NIK-dependent
phosphorylation and processing (Fong et
al., 2002). Notably, mutant forms of NF-
κB2 were detected in B and T cell lym-
phomas, where they are caused by
chromosomal translocations that result in
truncations of the regulatory C-terminal
Is NF-κB2/p100 a direct activator of programmed cell death?
Transcription factor NF-κB has been implicated in cancer development due to its ability to upregulate expression of genes
with potentially prooncogenic functions, such as cell cycle regulators and antiapoptotic proteins (Karin et al., 2002). A recent
report by Wang et al. (2002) suggests that a structural motif, a death domain (DD), present in one of the mammalian NF-κB
proteins, NF-κB2/p100, allows it to directly activate cell death in a transcription-independent manner. Further, it is suggested
that loss of the proapoptotic function of NF-κB2/p100 is directly linked to its oncogenic activity in lymphomas.
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domain, including the DD (Migliazza et
al., 1994). Invariably, these mutations
result in constitutive p52 production and
reduction of p100 (Figure 1). It has been
proposed that the constitutive production
of p52 and nuclear entry of p52:RelB
dimers lead to aberrant growth regulation
and/or suppression of apoptosis in
lymphocytes, thereby promoting lym-
phomagenesis (Karin et al., 2002). This
mechanism should be dependent on the
transcriptional activity of p52:RelB
dimers.
A different explanation for the trans-
forming potential of this chromosomal
rearrangement based on the elimination
of NF-κB2/p100 rather than p52 produc-
tion is proposed by Wang et al. (2002),
who suggest that recruitment of p100 via
its DD to death receptors, such as the
type I TNF receptor (TNFRI) or FAS,
leads to caspase 8 and caspase 3 acti-
vation and cell death. According to this
model, it is the loss of p100-mediated
cell death that contributes to lymphoma-
genesis. Unfortunately, several technical
and conceptual problems cast shadows
on this attractive scenario. Curiously, the
starting point for this work was the use of
a cell-free system to study induction of
p53-dependent cell death by ionizing
radiation (IR). Partially purified cell
extracts from irradiated p53 wt cells
(depleted of caspase 8) were screened
for their ability to activate caspases 8
and 3 in extracts of p53-deficient cells. A
series of chromatographic purification
steps yielded in a (still crude) fraction
that induced caspase 8 and 3 activation.
This fraction contained p100, in addition
to many other polypeptides. Depletion of
p100 from this fraction, but not from the
initial whole cell extract, reduced cas-
pase 3 activation. To study the functional
significance of this finding, the authors
undertook a series of overexpression
and underexpression experiments using
wt p100 and C-terminal truncations
thereof. Overexpression of p100 con-
ferred sensitivity to apoptosis triggered
by ligation of either TNFR1 or FAS, as
long as the DD in p100 was present.
Surprisingly, IR (whose mechanism of
induced cell death was the starting point
for this work) was not included in these
experiments as one of the proapoptotic
stimuli. Next, recruitment of p100 into
TNFRI and FAS signaling complexes
was investigated. Again, dependent on
its DD, p100 was found to be recruited to
activated TNFRI and FAS. Strikingly,
overexpression of the isolated DD of
p100 was sufficient to induce cell death.
To examine the relevance of all of this to
cancer, the authors show that wt p100,
but not its mature and DD-lacking form
p52, reduces RAS-induced transforma-
tion of NIH3T3 fibroblasts. In conclusion,
the authors suggest that p100 is an inte-
gral part of a death-inducing signaling
complex (DISC), acting independently of
its ability to give rise to the p52 transcrip-
tion factor and to sequester RelB in the
cytoplasm.
As mentioned above, both problems
inherent to this work and results
obtained by others question the physio-
logical relevance of this novel mecha-
nism. First, it is well established that IR
and FAS or TNFRI ligation trigger apop-
tosis through entirely different pathways
(Kumar and Vaux, 2002). Thus, it is diffi-
cult to understand why p100, recruited to
TNFRI or FAS, should be an active and
essential ingredient of an apoptosis-trig-
gered extract prepared from irradiated
p53wt cells. In vivo, caspase 8 is
required for apoptosis triggered by death
receptors, but not by DNA damaging
agents, whose proapoptotic action was
recently suggested to depend on cas-
pase 2 activation (Lassus et al., 2002).
Another limitation is that depletion of
p100 reduces the activity of a partially
purified fraction but does not reduce the
caspase activation ability of the unfrac-
tionated extract. Therefore, at best, the
complex containing p100 is one of sever-
al activities that promote caspase activa-
tion, whose physiological role in
IR-mediated apoptosis has not been
investigated. It is also not examined
whether reduced p100 expression
inhibits FAS-induced apoptosis. Given
that p100 may associate with a variety of
proteins and that some of these associa-
tions may occur after the cells are
homogenized, it is possible that immun-
odepletion of p100 may remove proapo-
ptotic mediators, although p100 itself
does not have such an activity, as sug-
gested by the analysis of p100-deficient
lymphocytes (see below). A different but
just as important limitation of this work is
that it is impossible to separate the DD
from p100 without affecting its process-
ing to p52, apart from experiments in
which the DD is investigated in isolation.
As outlined above, deletion of the DD
leads to constitutive generation of p52
and elimination of the IκB-like C-terminal
portion of p100. Thus, it is difficult to
understand why Wang et al. did not
detect enhanced p52 production from
Figure 1. NF-κB and IκB proteins
Schematic representation of the NF-κB pro-
teins RelA/p65, NF-κB2/p100, NF-κB2/p52,
IκBα, and tumor-derived mutants of NF-κB2.
The mutants, EB308 and LB40, were found in
a cutaneous T cell lymphoma (CTLC) and a
B cell chronic lymphocytic leukemia (B-CLL),
respectively (Migliazza et al., 1994). DD,
death domain; GRR, glycine rich region.
Established (IκBα) and putative (p100) serine
phosphoacceptor sites (S) are indicated.
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the truncated versions of p100 and
instead found that these polypeptides
can still inhibit NF-κB. It is possible that
expression of different amounts of p100
and its truncation mutants may result in
different and unpredictable outcomes,
ranging from induction of transcription
through p52:RelB dimers to inhibition of
NF-κB-dependent transcription of anti-
apoptotic genes through nonphysiologi-
cal titration of RelA or c-Rel. The
observed recruitment of p100 into the
DISCs, generated by TNFRI and FAS,
further complicates interpretation of the
original findings with the cell-free sys-
tem, as membrane-bound receptors and
their DISCs are expected to be excluded
from the cytosolic S100 extract.
Therefore, a different, non-membrane-
bound, p100-containing signaling com-
plex must be postulated to be activated
by IR. Even more difficult to explain is the
apoptotic activity of the isolated NF-κB2
DD. As DDs can only engage in bipartite
homotypic interactions (Hofmann, 1999),
it is difficult to envision how a single DD
can bridge two signaling molecules lead-
ing to caspase activation through the
well-established induced proximity
mechanism (Salvesen and Dixit, 1999).
In fact, an isolated DD can only be
expected to function as a dominant neg-
ative inhibitor of DD-mediated signaling
(Hofmann, 1999). Thus, it might be pos-
sible that expression of the p100 DD
leads to inhibition of p100 processing
and the accumulated p100 nonspecifi-
cally titrates off RelA and c-Rel.
Given the complexities of the experi-
mental approach used by Wang et al.,
one needs to consider what happens to
cells unable to express NF-κB2/p100.
Fortunately, three different mouse
mutants that lack p100 due to either a
complete knockout of the NF-κB2 gene
(Franzoso et al., 1998), removal of its 3′
half (Ishikawa et al., 1997), or ENU-
induced mutation (Miosge et al., 2002)
were described. According to Wang et
al., all of these mutations should invari-
ably result in suppression of apoptosis,
regardless of what happens to p52.
However, such an aberration has not
been described in mice lacking both
p100 and p52. On the contrary, detailed
analysis of xdr/xdr mice, which lack p100
and p52, reveals a B cell deficiency simi-
lar to the one caused by defective signal-
ing through the antiapoptotic BAFF-R
(Miosge et al., 2002). These aberrations
are very similar to those caused by the
absence of IKKα or NIK in B cells
(Senftleben et al., 2001). Rather than
causing their proapoptotic effect through
accumulation of p100, the NIK and IKKα
deficiencies are likely to sensitize B cells
to apoptosis by interfering with BAFF-R
signaling (Claudio et al., 2002). Most
likely, the chromosomal rearrangements
affecting the human NF-κB2 locus pro-
mote lymphomagenesis through a simi-
lar mechanism.
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